GlassScriptPhysician profile
Daniel Vernon Cahoon
NPI 1013985522
$17,960.12
in general payments reported to CMS, 2019-2025
30 companies · $794 in 2025
The $794 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $872 · 2020: $592 · 2021: $13K · 2022: $267 · 2023: $514 · 2024: $1,744 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,136 · Travel and Lodging: $916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,135.79 |
| Travel and Lodging | $915.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,564.17 | 2020-2023 | Da Vinci Surgical System |
| Boston Scientific Corporation | $1,651.50 | 2019-2025 | Lithovue, Lithoclast |
| Angiodynamics, INC. | $1,627.10 | 2023-2025 | Nanoknife |
| Astellas Pharma US INC | $342.09 | 2019-2022 | |
| Abbvie INC. | $305.57 | 2022-2025 | Botox |
| Procept Biorobotics Corporation | $197.08 | 2024-2025 | Aquabeam System |
| Calyxo, INC. | $191.78 | 2025 | Cvac Aspiration System |
| Coloplast Corp | $118.76 | 2023 | Altis |
| Pfizer INC. | $109.64 | 2019-2024 | |
| Allergan, INC. | $74.73 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $73.78 | 2019-2025 | Adstiladrin |
| Endo Pharmaceuticals INC. | $70.36 | 2020-2023 | Aveed, Xiaflex |
| Travere Therapeutics, INC. | $65.64 | 2019-2022 | |
| Lumenis, INC | $63.11 | 2021 | |
| Endo USA, INC. | $56.75 | 2025 | Xiaflex, Aveed |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $56.17 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $53.25 | 2023-2025 | Bridion |
| Janssen Biotech, INC. | $49.85 | 2019-2022 | |
| Laborie Medical Technologies Corp. | $43.96 | 2025 | |
| Sumitomo Pharma America, INC. | $36.26 | 2023 | Gemtesa |
| Antares Pharma, INC. | $31.53 | 2021 | |
| Myriad Genetic Laboratories, INC. | $30.63 | 2023 | Prolaris |
| Dendreon Pharmaceuticals LLC | $28.01 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.89 | 2019-2020 | |
| Urogen Pharma, INC. | $19.41 | 2021 | |
| Medtronic, INC. | $17.13 | 2024 | Interstim |
| Verity Pharmaceuticals INC. | $15.99 | 2023 | Trelstar |
| Astrazeneca Pharmaceuticals LP | $14.72 | 2021 | |
| Medtronic USA, INC. | $12.95 | 2019 | |
| Agiliti Surgical, INC. | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cahoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.